{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T22:29:21Z","timestamp":1781303361295,"version":"3.54.1"},"reference-count":29,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2001,12,24]],"date-time":"2001-12-24T00:00:00Z","timestamp":1009152000000},"content-version":"vor","delay-in-days":541,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2000,7]]},"abstract":"<jats:p> <jats:bold>\n            <jats:italic>Aims<\/jats:italic>\n          <\/jats:bold> Meloxicam is a novel nonsteroidal anti\u2010inflammatory drug (NSAID) which may be associated with fewer adverse upper gastrointestinal events than other NSAIDs because it preferentially inhibits the inducible enzyme cyclo\u2010oxygenase\u20102 relative to the constitutive isoform, cyclo\u2010oxygenase\u20101. The aims of the study were to: determine the rate of adverse events associated with meloxicam in general practice, stratify these rates by selected risk factors, and to identify signals of previously unsuspected adverse events associated with meloxicam.<\/jats:p><jats:p> <jats:bold>\n            <jats:italic>Methods<\/jats:italic>\n          <\/jats:bold> As part of the national prescription\u2010event monitoring pharmacovigilance system for newly launched drugs in general practice, all patients prescribed meloxicam in England between December 1996 and March 1997 were identified by the central Prescription Pricing Authority. We sent short questionnaires to all prescribers asking about adverse events experienced within 6\u2003months of the first prescription.<\/jats:p><jats:p> <jats:bold>\n            <jats:italic>Results<\/jats:italic>\n          <\/jats:bold> There were 19\u2003087 patients in the study. The rate of dyspepsia during the first month of exposure was 28.3 per 1000 patient\u2010months. There were 33 reports of upper gastrointestinal haemorrhage during treatment (rate: 0.4 per 1000\u2003months). A history of gastrointestinal disorder in the previous year was associated with an increased rate of dyspepsia (rate ratio: 3.0; 95% confidence interval: 2.6, 3.4), abdominal pain (2.1; 1.6, 2.6), and peptic ulcer (4.0; 1.4, 13.2). Prior NSAID use was associated with a 20\u201330% decrease in the rate of dyspepsia and abdominal pain in patients starting meloxicam, while patients prescribed concomitant gastroprotective agents had a two to three\u2010fold increased rate of dyspepsia, abdominal pain and peptic ulceration. Other rare events were thrombocytopenia (<jats:italic>n<\/jats:italic>\u2003=\u20032); interstitial nephritis (<jats:italic>n<\/jats:italic>\u2003=\u20031) and idiosyncratic liver abnormalities (<jats:italic>n<\/jats:italic>\u2003=\u20031).<\/jats:p><jats:p> <jats:bold>\n            <jats:italic>Conclusions<\/jats:italic>\n          <\/jats:bold> In the absence of gastro\u2010intestinal risk factors the incidence of gastro\u2010intestinal disturbance was low. Such risk factors should be carefully reviewed prior to prescribing meloxicam.<\/jats:p>","DOI":"10.1046\/j.1365-2125.2000.00229.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T04:39:13Z","timestamp":1047357553000},"page":"35-42","source":"Crossref","is-referenced-by-count":39,"title":["The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19\u2003087 patients in general practice in England: cohort study"],"prefix":"10.1111","volume":"50","author":[{"given":"Richard M.","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pipasha","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald D.","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,24]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.310.6983.817"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7119.1333"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)12154-2"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/37.9.937"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)03148-1"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.317.7151.119"},{"key":"e_1_2_7_8_2","volume-title":"International Drug Monitoring: the Role of the Hospital","author":"World Health Organisation.","year":"1966"},{"key":"e_1_2_7_9_2","unstructured":"WHO Collaborating Centre for International Drug Monitoring Uppsala Sweden. 14th Annual Meeting of Participating National Centres Barcelona September 30\u2010October 1 1991."},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(65)90054-8"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.6101.1523"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)78800-0"},{"issue":"1","key":"e_1_2_7_13_2","first-page":"1","article-title":"The incidence of the most commonly reported events with 40 newly marketed drugs \u2013 study by Prescription\u2010Event Monitoring","volume":"6","author":"Freemantle SN","year":"1997","journal-title":"Pharmacoepidemiol Drug Safety"},{"key":"e_1_2_7_14_2","volume-title":"British National Formulary","author":"Joint Formulary Committee.","year":"1998"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"e_1_2_7_16_2","doi-asserted-by":"crossref","unstructured":"MannRD WiltonLV PearceGL MackayFJ DunnNR.Prescription\u2010Event Monitoring (PEM) in1996\u2013 a method of non\u2010interventional observational cohort pharmacovigilance.Pharmacoepidemiol Drug Safety1997;3:S5\u2013S11.","DOI":"10.1002\/(SICI)1099-1557(199710)6:3+<S5::AID-PDS272>3.3.CO;2-6"},{"key":"e_1_2_7_17_2","unstructured":"StataCorp.Stata Statistical Software: Release 5.0.College Station TX. Stata Corporation 1997."},{"key":"e_1_2_7_18_2","unstructured":"International Ethical Guidelines for Biomedical Research Involving Human Subjects. CIOMS\/WHO Geneva1993."},{"key":"e_1_2_7_19_2","unstructured":"Guidelines on the practice of Ethical Committees in Medical Research involving Human Subjects.Royal College of Physicians of London. August1996."},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(98)80647-1"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1997.v112.pm9024292"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0701672"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803123381105"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)91763-C"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.307.6912.1118"},{"key":"e_1_2_7_26_2","unstructured":"LastJM.A dictionary of epidemiology 3rd edition. Oxford:Oxford University Press 1995."},{"issue":"2","key":"e_1_2_7_27_2","first-page":"S100","article-title":"Nicorandil and diabetes: examination of an hypothesis generated by prescription\u2010event monitoring","volume":"7","author":"Dunn N","year":"1998","journal-title":"Pharmacoepidemiol Drug Safety"},{"issue":"2","key":"e_1_2_7_28_2","first-page":"S18","article-title":"Visual field defects in patients taking vigabatrin","volume":"6","author":"Stephens MDB","year":"1997","journal-title":"Pharmacoepidemiol Drug Safety"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.319.7218.1165"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117620"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2125.2000.00229.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2125.2000.00229.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2125.2000.00229.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T15:37:26Z","timestamp":1698593846000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2125.2000.00229.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,7]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2000,7]]}},"alternative-id":["10.1046\/j.1365-2125.2000.00229.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2125.2000.00229.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,7]]}}}